Navigation Links
Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Date:9/4/2009

DEERFIELD, Ill. and OSAKA, Japan, Sept. 4 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl). The FDA informed Takeda on June 26, 2009 that further review of the alogliptin monotherapy NDA would be conditional based upon additional data from a cardiovascular (CV) safety study that satisfies the statistical requirements of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes."

"This complete response letter from the FDA is consistent with the June 26 complete response letter for alogliptin, a key component of the alogliptin and ACTOS fixed-dose combination product," said Nancy Joseph-Ridge, M.D., general manager, Pharmaceutical Development Division. "The FDA recently agreed to the study design for a cardiovascular outcomes trial for alogliptin, titled EXAMINE, and patient enrollment is planned to begin this month. We anticipate that the EXAMINE trial will provide the FDA with the information needed to continue the NDA reviews of both the alogliptin monotherapy and the alogliptin and ACTOS fixed-dose combination."

The complete response letter was specific to the FDC of alogliptin and ACTOS, and did not include any new questions or concerns about alogliptin or ACTOS.

About ACTOS(R) (pioglitazone HCl)

ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diab
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
2. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
3. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
4. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
5. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
6. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
7. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
8. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
10. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... UHC has released the findings of a new study ... cost and quality outcomes to uncover several trends related ... utilization of PPIs—which can account for 30% to 40% ... medical centers, focusing on procedures utilizing orthopedic implants, coronary ... The study, begun in 2013, integrated the pilot test ...
(Date:3/31/2015)... , March 31, 2015 Point-of-Care ... and management consulting firm, has launched the ePA ... enable health IT vendors, payers and pharmacies to ... electronic prior authorization (ePA) of prescription medications. ... (PA) requests are completed through time-consuming, manual processes ...
(Date:3/31/2015)... 31, 2015  The efficacy of continuous UV-C disinfection ... recently published study 1 of ultraviolet (UV) light ... including Curtis Donskey , M.D.  The study tested ... same length of time from the same point in ... results showed surprisingly low pathogen kill rates for the ...
Breaking Medicine Technology:UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Point-of-Care Partners Launches the ePA State Navigator 2VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 2VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 3VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 4
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated ... products and bioimplants processed from human amniotic membrane, ... the Company,s latest biologic implant processed to offer ... Produced from the MiMedx Group,s proprietary Purion® ...
... Cardinal Health today announced that its board of directors has approved ... per share, or $0.86 per share on an annualized basis. ... shareholders of record on July 1. Cardinal Health has paid a ... This marks the 107th consecutive regular quarterly dividend for Cardinal Health. ...
Cached Medicine Technology:MiMedx Announces Launch of AmnioFix™ Nerve Wrap 2Cardinal Health Raises Quarterly Dividend By 10 Percent 2Cardinal Health Raises Quarterly Dividend By 10 Percent 3
(Date:3/31/2015)... March 31, 2015 Simeon Boyd, UC ... nearly $4 million, five-year grant from the National Institute ... of physicians and scientists from more than 10 centers ... Australia, Brazil, Bulgaria, Germany, Hungary, Italy and the United ... bony plates of the skull in infants. , The ...
(Date:3/31/2015)... OnChip Devices , a world leader in Integrated ... chip targeted towards low voltage LED applications. Adding to its ... for protecting circuits by suppressing voltage higher than 3.0 Volts. ... up to 350W and 20A, providing protection of 8kV when ... These diodes do not exhibit any device degradation when compared ...
(Date:3/31/2015)... March 31, 2015 Clinovo, a ... BayBio’s Membership Program , the premiere voice of ... 1300+ life science companies. , BayBio brings ... world’s most innovative and productive life science cluster, ... some of humanity’s most pressing challenges. , ...
(Date:3/31/2015)... At Summit Breast Care, their passion is ... calm and caring manner. , Summit Breast Care has achieved ... of breast cancer. They treat thousands of patients annually, ... the world. Their doctors continue to be recognized as ... for Summit Breast Care were planted in the mind and ...
(Date:3/31/2015)... 2015 Beckman Coulter is sponsoring a ... “Subvisible Particulate Matter in Therapeutic Protein Injections”,” an educational session ... in counting particles in liquids, with a focus on the ... free to attend and will be broadcast live April 8, ... new test for protein-based materials, known as USP 787 ...
Breaking Medicine News(10 mins):Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 2Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 3Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 3
... Dr. Love has ambitious plans to educate the world ... and the world's most populous Muslim nation, Indonesia . ... Love" for his flamboyant, unconventional methods of sex education ... ,They are invited to send anonymous text messages ...
... Leading US drug manufacturer, Jazz Pharmaceuticals, has agreed to ... claims that one of its subsidiaries illegally marketed ... ,Narcolepsy is a sleep disorder marked by sudden, uncontrollable ... at inappropriate times. ,,The case is the ...
... new target for anti-cancer drugs, by focusing on the protein ... gene implicated in almost one-third of all cancers. ... studied the gene known as Ras, which is integral in ... overactive, it can lead to the unregulated proliferation of cells ...
... on fire and engineering insurance is set to have ... particularly health insurance . , This would be ... drive down the premiums in marine, fire and engineering ... up for loss-making sectors like health and motor insurance. ...
... pending at the Waikato hospital owed by the health care ... taxpayer-funded health care facilities to which they are not eligible ... do they hold a valid New Zealand passport. ,These ... the tax paying citizens. ,Last week Waikato District Health ...
... is a wonderful hobby but one has to take care of ... of hazardous and harmful plants that children and the adult ... for example is the most common of them all. This weedy ... contact dermatitis in Britain. This year, an increase in the concentration ...
Cached Medicine News:Health News:Singapore's Dr. Love Brings Good Sex to Indonesia 2Health News:Singapore's Dr. Love Brings Good Sex to Indonesia 3Health News:Manufacturer to Pay $20 Million for Improperly Promoting a Sleep Disorder Drug 2Health News:Manufacturer to Pay $20 Million for Improperly Promoting a Sleep Disorder Drug 3Health News:Researchers Find New Target for Anti-cancer Drugs 2Health News:Health Insurance- Play It Safe And Reap The Benefits 2Health News:Health Insurance- Play It Safe And Reap The Benefits 3Health News:$1 Million Unpaid Bills by Health Care Cheats at Waikato Hospital 2Health News:Dangers Lurking in the Garden in Britain 2Health News:Dangers Lurking in the Garden in Britain 3
... Air-Stirrup Ankle Brace has been the "standard ... ankle injuries and has been cited in ... performance in helping to heal ankle injuries.,Each ... lined with the patented Duplex™ aircell system. ...
... Cryo/Cuff combines the therapeutic benefits of controlled ... cold to minimize pain. The cuff is ... providing maximum cryotherapy. The Ankle Cryo/Cuff is ... in a pediatric size.,All Cryo/Cuffs can be ...
... Plus combines the clinically proven Air-Stirrup ... In addition, a comprehensive instruction booklet ... and provides information on treatment and ... sprain management.,Each Air-Stirrup Ankle Brace features ...
... exclusively with the Aircast VenaFlow System (a ... in three different styles: calf, foot, and ... cuff is made from light, cool, comfortable ... the cuff may be placed directly against ...
Medicine Products: